MENU
SLDB
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Solid Biosciences (SLDB) Earnings Date & Reports
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases... Show more
Industry: #Biotechnology
A.I. Advisor
published Earnings
SLDB is expected to report earnings to rise 9.08% to -41 cents per share on November 11
Q3'26
Est.
$-0.41
Q2'26
Beat
by $0.07
Q1'26
Beat
by $0.13
Q4'25
Beat
by $0.09
Q3'25
Beat
by $0.17
The last earnings report on August 06 showed earnings per share of -37 cents, beating the estimate of -44 cents. With 371.70K shares outstanding, the current market capitalization sits at 780.60M.
View a ticker or compare two or three
VS
VS
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
Interesting Articles
A.I. Advisor
published General Information
General Information
a developer of novel gene therapy platform for advancing disease
Industry Biotechnology
Industry
Biotechnology
Address
500 Rutherford Avenue
Phone
+1 617 337-4680
Employees
121
Web
https://www.solidbio.com